Evidence map›Paper›PMID 40268927›Full record

ArticleNature communications2025

Cellular immunotherapy targeting CLL-1 for juvenile myelomonocytic leukemia.

Juwita Werner, Alex G Lee, Chujing Zhang, Sydney Abelson, Sherin Xirenayi, Jose Rivera, Khadija Yousuf, Hanna Shin, Bonell Patiño-Escobar, Stefanie Bachl and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Heterogeneity of monocytes in cancer.American journal of cancer research · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Juwita Werner *Department of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0009-0007-9635-2519
Alex G Lee *Department of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, CA, USA.
Chujing ZhangDepartment of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, CA, USA.
Sydney AbelsonDepartment of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, CA, USA.
Sherin XirenayiDepartment of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, CA, USA.
Jose RiveraDepartment of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, CA, USA.
Khadija YousufDepartment of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, CA, USA.
Hanna ShinDepartment of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, CA, USA.
Bonell Patiño-EscobarDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-2622-4822
Stefanie BachlDepartment of Medicine, University of California, San Francisco, CA, USA.
Kamal MandalDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Abhilash BarpandaDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Emilio RamosDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Adila IzgutdinaDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-3296-3261
Sibapriya ChaudhuriDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, USA.
William C TempleDivision of Pediatric Allergy, Immunology, and Bone Marrow Transplant, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-3375-2703
Shubhmita BhatnagarDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Jackson K DardisDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Julia MeyerDepartment of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, CA, USA.
Carolina MoralesDepartment of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, CA, USA.
Soheil MeshinchiClinical Research Division, Department of Pediatrics, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Mignon L LohSeattle Children's Hospital, The Ben Towne Center for Childhood Cancer Research, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-4099-4700
Benjamin BraunDepartment of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, CA, USA.
Sarah K TasianDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-1327-1662
Arun P WiitaDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-7465-6964
Elliot StieglitzDepartment of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, CA, USA. elliot.stieglitz@ucsf.edu.ORCID http://orcid.org/0000-0001-7032-4623

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Alan Ashworth · 1999 to 2026
$209.7M
Project 4: Secondary Cancers Among NF1 Cancer SurvivorsU54CA196519 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI KEVIN M. SHANNON · 2015 to 2026
$26.9M
Implementation of an interventional, risk-adapted clinical trial for children with newly diagnosed juvenile myelomonocytic leukemia.R37CA266550 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Elliot Stieglitz · 2022 to 2026
$3.4M
Utilizing Multi-omics to Facilitate Cancer Biology ResearchR50CA274213 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Alex Lee · 2023 to 2026
$935k
NCI NIH HHS P30 CA082103NCI NIH HHS R37 CA266550NCI NIH HHS R50 CA274213NCI NIH HHS U54 CA196519
6 · The paper itself

Abstract

Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative disorder that predominantly affects infants and young children. Hematopoietic stem cell transplantation (HSCT) is standard of care, but post-HSCT relapse is common, highlighting the need for innovative therapies. While adoptive immunotherapy with chimeric antigen receptor (CAR) T cells has improved outcomes for patients with advanced lymphoid malignancies, it has not been comprehensively evaluated in JMML. In the present study, we use bulk and single-cell RNA sequencing, mass spectrometry, and flow cytometry to identify overexpression of CLL-1 (encoded by CLEC12A) on the cell surface of cells from patients with JMML. We develop immunotherapy with CLL-1 CAR T cells (CLL1CART) for preclinical testing and report in vitro and in vivo anti-leukemia activity. Notably, CLL1CART reduce the number of leukemic stem cells and serial transplantability in vivo. These preclinical data support the development and clinical investigation of CLL-1-targeting immunotherapy in children with relapsed/refractory JMML.

Indexed as

Immunotherapy, AdoptiveLectins, C-TypeLeukemia, Myelomonocytic, JuvenileReceptors, MitogenAnimalsChildFemaleHumansInfantMaleMiceMice, SCIDNeoplastic Stem CellsReceptors, Chimeric AntigenT-LymphocytesXenograft Model Antitumor AssaysCLEC12A protein, humanLectins, C-TypeReceptors, Chimeric AntigenReceptors, Mitogen

Identifiers

PMID40268927
PMCPMC12019388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.